ABBVIE INC. (ABBV)
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohns Disease
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohns Disease
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business